Cecilia Hofvander (Alligator Bioscience AB (Nasdaq Stockholm: ATORX))

Hofvander, Cecilia (BioInvent 202207 Senior Director IR before Alligator Bioscience)

	Organisation	Alligator Bioscience AB (Nasdaq Stockholm: ATORX)
	Group	Alligator Bioscience (Group)
	Product	public relations / investor relations / marcom (services)
	Product 2	cancer immunotherapy (immuno-oncology, I-O)
	Source	BioInvent International AB. (7/12/22). "Press Release: BioInvent Has Successfully Carried Out a Directed Share Issue of approximately SEK 300 Million (approximately USD 28.3 Million) [ Not for US, AU, et al. ]". Lund.

Record changed: 2024-07-17

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Cecilia Hofvander

[1] BioInvent International AB. (7/12/22). "Press Release: BioInvent Has Successfully Carried Out a Directed Share Issue of approximately SEK 300 Million (approximately USD 28.3 Million) [ Not for US, AU, et al. ]". Lund....
[2] Alligator Bioscience AB. (2/12/20). "Press Release: Alligator Bioscience AB Year-end Report January-December 2019"....
[3] Alligator Bioscience AB. (12/17/19). "Press Release: First Patient Dosed with ATOR-1017 Developed for Metastasized Cancer". Lund....
[4] Alligator Bioscience AB. (8/20/19). "Press Release: Alligator Bioscience Signs Antibody Agreement for Greater China with Biotheus Inc.". Lund....
[5] Alligator Bioscience AB. (1/7/19). "Press Release: Alligator Bioscience Launches RUBY, a Novel Concept in Bispecific Antibody Formats". Lund....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]